化合物 BV6|T6428|TargetMol

價(jià)格	￥373	￥497	￥675
包裝	1mg	2mg	5mg

最小起訂量	1mg
發(fā)貨地	上海
更新日期	2024-12-12

QQ交談微信洽談

產(chǎn)品詳情

中文名稱:化合物 BV6	英文名稱:BV6
CAS:1001600-56-1	品牌: TargetMol
產(chǎn)地: 美國(guó)	保存條件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
純度規(guī)格: 99.89%	產(chǎn)品類別: 抑制劑
貨號(hào): T6428

Product Introduction

Bioactivity

名稱	BV6
描述	BV6 is an antagonist of c-IAP1 and XIAP, members of the inhibitors of apoptosis (IAP) family.
細(xì)胞實(shí)驗(yàn)	BV6 is prepared in DMSO and stored, and then diluted with appropriate medium before use. H460 and HCC193 cell lines are cultured in RPMI-1640 supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Cell viability is measured using the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay kit. 5000 cells/well are seeded into 96-well plates in triplicate. Following adhesion of cells to the wells, increasing concentrations of BV6 are added into different wells. Control groups are exposed to the same concentration of DMSO. The final concentrations of 333 μg/mL MTS and 25 μM PMS are added to each well 24 hours later. After two hours incubation at 37°C in humidified 5% CO2, plates are read at the absorbance of 490 nm on a microplate reader. Relative cell viability of an individual sample is calculated by normalizing their absorbance to that of the corresponding control. IC50 values are calculated using Prism 5.01. For the TNFα neutralizing antibody assay, cells are exposed to 1 and 5 μM BV6 with or without 10 μg/mL Infliximab and the assay is performed 24 hours later. Plates are read at the absorbance of 490 nm on a microplate reader.
動(dòng)物實(shí)驗(yàn)	BV6 is prepared in DMSO and diluted with saline or PBS. Female mice (6 weeks of age, BALB/c) are used. All 24 mice are ovariectomized through a 1 cm longitudinal skin incision then injected s.c. with estradiol valerate (0.5 μg/mouse/week) once per week for 6 weeks until the experimental endometriosis induction. Two weeks after ovariectomy, the uteri of an additional eight donor mice (n=8) are removed en bloc after euthanasia and cleaned of excess tissue in sterile saline. Each uterus is cut to include the uterine horns in each half with a linear incision longitudinally and minced (0.5 mm in diameter) with dissecting scissors. The ovariectomized recipient mice (n=16) are anesthetized using pentobarbital sodium. A 0.5 cm subabdominal midline incision is made. Each recipient receives half of the donor uterus (1:2 donor uterus to host ratio) minced and added to 500 μl saline, and injected into the peritoneal cavity, and the peritoneum is sutured. Injected uterine tissue weighed ~50 mg per mouse. For the next 4 weeks, recipient mice are treated with a single i.p. injection of BV6 (n=8; 10 mg/kg) or vehicle (n=8; 1% DMSO) twice weekly.
體外活性	對(duì)HCC193細(xì)胞處理1 μM BV6 24小時(shí)，相對(duì)于DMSO處理的細(xì)胞，HCC193細(xì)胞的生存曲線顯著偏移，DER=1.38 (p<0.05)。BV6 (2和5 μM) 顯著抑制異位和原位（無病和肌瘤）ESC中的BrdU合成。在使用5 μM BV6處理后，兩組中BrdU合成均約減少30%。向HCC193細(xì)胞施加1 μM BV6后，治療1小時(shí)即完全耗盡cIAP1水平，而XIAP水平減少則在化合物添加24小時(shí)后才出現(xiàn)。同樣，5 μM BV6在1小時(shí)內(nèi)完全耗盡H460細(xì)胞中的c-IAP1，并在24小時(shí)后開始減少XIAP。與此平行的發(fā)現(xiàn)是，對(duì)于兩種細(xì)胞系，0.25 μM BV6的小劑量就能減少c-IAP1水平，而在5 μM BV6時(shí)，仍可觀察到少量的XIAP。從與1 μM BV6孵育12小時(shí)后開始，HCC193細(xì)胞顯著出現(xiàn)切割型caspase-3水平，且這一水平在48小時(shí)內(nèi)隨時(shí)間增長(zhǎng)而持續(xù)增加。
體內(nèi)活性	小鼠c-IAP-1、c-IAP-2和XIAP表達(dá)在植入體的上皮細(xì)胞和基質(zhì)細(xì)胞的細(xì)胞質(zhì)中清晰可見，而Survivin主要表達(dá)在核內(nèi)。經(jīng)過4周的BV6處理后，IAPs表達(dá)的強(qiáng)度減弱。免疫組化染色后，角蛋白和波形蛋白呈陽性染色，而鈣結(jié)合蛋白陰性。采用BV6治療4周后，病變的總數(shù)（4.6對(duì)2.8/只小鼠）、平均重量（78.1對(duì)32.0 mg/只小鼠）和表面積（44.5對(duì)24.6 mm2/只小鼠）顯著低于對(duì)照組。在子宮內(nèi)膜腺上皮或基質(zhì)中，Ki67陽性細(xì)胞的百分比在BV6治療后降低。
存儲(chǔ)條件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 55 mg/mL (45.62 mM)
關(guān)鍵字	inhibit \| Inhibitor \| BV6 \| BV 6 \| IAP \| BV-6
相關(guān)產(chǎn)品	LCL161 \| MX69 \| Xevinapant \| Acacetin \| Birinapant \| 1-[2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one \| ASTX660 \| N-Deshydroxyethyl Dasatinib \| Se-Methylselenocysteine \| AZD5582 TFA \| GDC-0152 \| HM90822
相關(guān)庫	經(jīng)典已知活性庫 \| 已知活性化合物庫 \| 細(xì)胞凋亡化合物庫 \| NO PAINS 化合物庫 \| PPI抑制劑庫

關(guān)鍵字： BV6|TargetMol

公司簡(jiǎn)介

TargetMol Chemicals Inc. 總部位于馬薩諸塞州波士頓，致力于為全球生化領(lǐng)域科學(xué)家的研究提供專業(yè)的產(chǎn)品和服務(wù)。TargetMol?品牌的客戶群分布于40多個(gè)國(guó)家和地區(qū)，已發(fā)展成為全球知名的化合物庫和小分子化合物研究供應(yīng)商。 TargetMol?可提供160多種滿足不同需求的化合物庫，以及多種類型的生化試劑產(chǎn)品，包括12000多種抑制劑、16000多種天然產(chǎn)物和各類多肽、抗體、生命科學(xué)試劑盒等，此外，我們還建設(shè)有CADD（計(jì)算機(jī)輔助藥物設(shè)計(jì)）研究中心、藥理實(shí)驗(yàn)室、藥化合成平臺(tái)三大技術(shù)中心，全方位滿足客戶的定制需求。憑借我們優(yōu)質(zhì)的產(chǎn)品和服務(wù)、快速高效的全球供應(yīng)鏈和專業(yè)的技術(shù)支持，我們將有效幫助您縮短研發(fā)周期，取得更成功的結(jié)果。

成立日期	2013-04-18 （12年）	注冊(cè)資本	566.265100萬人民幣
員工人數(shù)	100-500人	年?duì)I業(yè)額	￥ 1億以上
主營(yíng)行業(yè)	天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù)	經(jīng)營(yíng)模式	貿(mào)易,工廠,試劑,定制,服務(wù)

TargetMol中國(guó)（陶術(shù)生物）

VIP 3年

公司成立：12年
注冊(cè)資本：566.265100萬人民幣
企業(yè)類型：有限責(zé)任公司(自然人投資或控股)
主營(yíng)產(chǎn)品：小分子抑制劑、藥物篩選化合物庫、藥物篩選等
公司地址：靜安區(qū)江場(chǎng)三路238號(hào)8樓

進(jìn)入店鋪

詢盤

店內(nèi)推薦

化合物 Apelin-17(human, bovine)|TP2092|TargetMol

￥5750

化合物 ANO1-IN-1|T61051|TargetMol

￥185

弗斯特羅定|T9419|TargetMol

￥218